Gilead的HIV-1卡比塞抑制剂Lenacapavir在一次试验中将新感染艾滋病毒的人数减少了96%,超过了特鲁瓦达。 Gilead's HIV-1 capsid inhibitor, lenacapavir, reduced new HIV infections by 96% in a trial, outperforming Truvada.

吉利德科学公司报告称,其HIV-1囊抑制剂莱纳卡巴维尔在晚期试验中,使新感染HIV的数量减少了96%,超过每日服用的Truvada药片. Gilead Sciences has reported that its HIV-1 capsid inhibitor, lenacapavir, reduced new HIV infections by 96% in a late-stage trial, outperforming the daily pill Truvada. 独立委员会建议停止盲目的研究,向所有参与者提供莱纳卡帕维尔。 The independent committee recommended halting the blinded study to offer lenacapavir to all participants. 吉利德计划在2024年底提交FDA批准,并计划在2025年推出市场. Gilead plans to submit for FDA approval by late 2024, aiming for a market launch in 2025. 然而,Lenacapavir的潜在成本很高,对普遍获得服务构成挑战。 However, the high potential cost of lenacapavir poses challenges for widespread access.